Dupixent

September had several clinical trial results announcements and a few FDA approvals triggering moves in the space. New molecular moiety, or NME, approvals totalled a mere three in September, taking the total NME approvals for 2018 to 37 compared to 46 in 2017. Here are the PDUFA catalysts for...

Regeneron Pharmaceuticals Inc (NASDAQ: REGN) shares fell 31 percent over the last six months, and the company's headwinds appear unending. The biotech firm lost an advocate Wednesday on the basis of a rough outlook for Eylea and Dupixent treatments. The Rating Canaccord Genuity analyst John...

Analysts at Baird Equity Research turned bearish on Regeneron Pharmaceuticals Inc (NASDAQ: REGN) as investor expectation for a recently launched drug may be too high. The firm's Brian Skorney downgrades Regeneron's stock rating from Neutral to Underperform with an unchanged $408 price target....

Regeneron Pharmaceuticals Inc (NASDAQ: REGN) shares have been on an uptrend since late April, adding roughly 40 percent. The run up has led to worries over whether the stock has gotten ahead of fundamentals. Bernstein downgraded Regeneron, citing a more balanced risk-reward scenario. The firm...

Atopic dermatitis treatment candidate Dupixent jointly developed by Regeneron Pharmaceuticals Inc (NASDAQ: REGN) and Sanofi SA (ADR)(NYSE: SNY) has scaled the regulatory hurdle, a day ahead of the scheduled FDA examination day. The companies said the FDA has okayed Dupixent Injection, the first...

In its biopharma catalysts tracker released March 1, Leerink termed the year 2017 as a busy one for Neuro and Oncology. The firm highlighted the important catalysts for 2017. Celgene — Multiple Readout In 2017 On Celgene Corporation (NASDAQ: CELG), the firm noted that it has multiple readouts...